Administer orally, preferably 15-30 minutes before meals for optimal absorption. Shake the suspension well before each use. Use a measuring cup or syringe for accurate dosing.

Domperidone selectively blocks dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and peripherally in the gastrointestinal tract. This action increases lower esophageal sphincter tone and improves gastric emptying, thereby reducing nausea and vomiting.

• •Hypersensitivity to domperidone or any excipients.
• •Prolactin-releasing pituitary tumor (prolactinoma).
• •Patients with known existing prolongation of cardiac conduction intervals, particularly QTc, or significant electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia), or underlying cardiac diseases (e.g., congestive heart failure).
• •Moderate to severe hepatic impairment.
• •Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin, ritonavir).
• •Conditions where stimulation of gastric motility could be harmful (e.g., gastrointestinal hemorrhage, mechanical obstruction, perforation).

Store below 30°C, protected from light and moisture. Do not freeze. Keep out of reach of children.

Symptoms of overdose may include somnolence, disorientation, and extrapyramidal reactions. Management is supportive and symptomatic, including gastric lavage and activated charcoal. ECG monitoring is recommended due to the risk of cardiac arrhythmias.

Pregnancy: Limited data on human pregnancy. Should only be used if the potential benefits outweigh the potential risks to the fetus and under strict medical supervision. Lactation: Domperidone is excreted in breast milk in small amounts. A risk to the breastfed infant cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from domperidone therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.